The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| KVUE | -18.35% | N/A | N/A | -29% |
| S&P | +11.09% | +81.2% | +12.62% | +66% |
Kenvue, Inc. engages in the provision of healthcare products services. It operates through the following business segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care and hair, sun and others. The Essential Health segment includes oral care, baby care, women’s health and wound care. The company was founded on February 23, 2022 and is headquartered in Skillman, NJ.
Kimberly-Clark is creating a consumer health and wellness giant.
Even though Kenvue's stock was already in a tailspin before the FDA warned pregnant woman that Tylenol posed a health risk, there are still some lingering impacts to consider.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $3.76B | -3.5% |
| Gross Profit | $2.22B | -2.9% |
| Gross Margin | 59.00% | 0.4% |
| Market Cap | $31.15B | -29.7% |
| Market Cap / Employee | $1.42M | 0.0% |
| Employees | 22K | 0.0% |
| Net Income | $398.00M | 3.9% |
| EBITDA | $854.00M | -3.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.14B | 7.8% |
| Accounts Receivable | $2.42B | 0.9% |
| Inventory | 1.8K | -1.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $7.16B | 0.3% |
| Short Term Debt | $1.95B | 15.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 5.29% | 1.3% |
| Return On Invested Capital | 6.07% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $196.00M | 3.2% |
| Operating Free Cash Flow | $294.00M | 18.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 40.22 | 43.22 | 28.37 | 22.07 | -47.42% |
| Price to Book | 3.84 | 4.75 | 4.00 | 2.90 | -33.31% |
| Price to Sales | 2.69 | 2.98 | 2.66 | 2.10 | -27.31% |
| Price to Tangible Book Value | -5.43 | -6.00 | -5.24 | -4.12 | -29.72% |
| Price to Free Cash Flow TTM | 146.05 | 718.87 | 553.96 | - | |
| Enterprise Value to EBITDA | 64.29 | 68.05 | 53.61 | 46.31 | -22.24% |
| Free Cash Flow Yield | 0.7% | 0.1% | 0.2% | - | |
| Return on Equity | 9.9% | 10.2% | 13.6% | 13.5% | 36.32% |
| Total Debt | $8.72B | $8.85B | $8.74B | $9.11B | 3.19% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
